A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

ClinicalTrials.gov ID: NCT05371964

Public ClinicalTrials.gov record NCT05371964. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 26, 2026, 6:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Study identification

NCT ID: NCT05371964
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Geron Corporation; Industry
Enrollment: 36 participants

Conditions and interventions

Conditions

Myelofibrosis

Interventions

Imetelstat sodium Drug
Ruxolitinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 3, 2022
Primary completion: Jan 31, 2027
Completion: Jul 31, 2028
Last update posted: Jan 5, 2026

2022 – 2028

United States locations

U.S. sites: 8
U.S. states: 5
U.S. cities: 8

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
City of Hope	Irvine	California	92618	Recruiting
University of Miami	Coral Gables	Florida	33146	Recruiting
H. Lee Moffitt Cancer Center and Research Institute, Inc.	Tampa	Florida	33612	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Texas Oncology	Denison	Texas	75020	Withdrawn
Texas Oncology	Tyler	Texas	75702	Withdrawn
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05371964, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 5, 2026 · Synced Jun 26, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05371964 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →